The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine.
The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine.
复制标题
DOI：
10.1097/wnp.0b013e318230da8a
复制
发表时间：
2011-10
期刊：
影响因子：
--
通讯作者：
Leuchter AF
中科院分区：
文献类型：
--
作者：
Hunter AM;Cook IA;Greenwald SD;Tran ML;Miyamoto KN;Leuchter AF
Recent research aims at developing a biomarker to predict antidepressant treatment outcomes in Major Depressive Disorder (MDD). The Antidepressant Treatment Response index (ATRindex) has been correlated with response to antidepressant medication but has not been assessed in a placebo-controlled trial. EEGs were used to calculate ATR-index for 23 randomized MDD subjects to eight weeks of fluoxetine treatment (FLX) 20 mg (n=12) or placebo (n=11). The 17-item Hamilton Depression Rating Scale (HamD17) assessed symptom severity, while a percent change in HamD17 score, endpoint response (≥ 50% improvement) and remission (HamD17 score ≤ 7) were used to assess ATR-index as a predictor. ATR-index was significantly associated with improvement on FLX (r = .64, p = .01), with a higher mean ATR-index for FLX responders than non-responders (t(10)= −2.07, p=0.03). Receiver Operating Characteristic analysis found a .83 area under the curve (p = .03), for ATR-index as a predictor for FLX, while an optimized ATR-index cutoff of 47.3 yielded 100% sensitivity, 66.7% specificity, 75% PPV and 100% NPV. Importantly, ATR-index did not correlate significantly with placebo outcomes. Results extend ATR-index findings to include predictive validity with fluoxetine, suggesting that this biomarker has specificity for drug effects.
